Researchers recently reported in JCO Oncology Advances that short-course vaginal cuff brachytherapy (VCB) offers an effective alternative to standard fractionation regimens for adjuvant treatment of early-stage endometrial cancer. Their multicenter randomized trial compared two-fraction regimens (11 Gy × two fractions) to conventional protocols (7 Gy × three fractions, 6 Gy × five fractions, or 5-5.5 Gy × four fractions) in terms of patient-reported quality of life (QOL), adverse effects, and cancer control outcomes. Results demonstrated that the experimental arm maintained noninferior QOL at 1-, 6-, and 12-months post-treatment without increased acute toxicity. Both regimens achieved high vaginal control rates of 96%, supporting the shorter protocol as a viable option for improving treatment efficiency without compromising outcomes. The trial highlighted that short-course VCB reduces resource demands, logistical barriers, and treatment-associated stress for patients, particularly those in rural or underserved areas. Acute toxicity, including gastrointestinal and sexual side effects, was comparable across regimens, with fewer urinary adverse events reported in the experimental arm. However, the study did not evaluate long-term sexual health or late toxicity outcomes, areas requiring further research. Additionally, while the shorter regimen minimizes treatment time and cost, its effect on financial toxicity remains unexplored, prompting further investigation through the SAVE-2 protocol. Overall, short-course VCB demonstrates the potential to enhance the patient experience and expand access to care for endometrial cancer